VivoSim Labs (VIVS) Total Current Liabilities (2011 - 2026)
VivoSim Labs (VIVS) posted quarterly Total Current Liabilities of $2.8 million for Q1 2026, down 25.47% year-over-year from $3.7 million in Q1 2025, and up 12.53% quarter-over-quarter from $2.5 million in Q4 2025.
VivoSim Labs (VIVS) Total Current Liabilities (2011 - 2026) Analysis & Trends
VivoSim Labs' Total Current Liabilities history runs 16 years deep, the most recent figure standing at $2.8 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 25.47% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $2.8 million (down 25.47% YoY), while the FY2026 annual figure was $2.8 million, down 25.47% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $2.8 million, up from $2.5 million in the prior quarter.
- The five-year high for Total Current Liabilities was $3.7 million in Q1 2025, with the low at $1.3 million in Q2 2022.
- The 5-year median for Total Current Liabilities is $2.0 million (2024), against an average of $2.2 million.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities soared 165.44% in 2023, then plunged 49.33% in 2024.
- VivoSim Labs' Total Current Liabilities stood at $1.4 million in 2022, then increased by 23.55% to $1.7 million in 2023, then surged by 72.76% to $2.9 million in 2024, then slipped by 15.73% to $2.5 million in 2025, then grew by 12.53% to $2.8 million in 2026.
- Business Quant data shows VIVS's Total Current Liabilities at $2.8 million in Q1 2026, $2.5 million in Q4 2025, and $2.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | VivoSim Labs | 1.49 Mn | 1.49 Mn | - | 1.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.90 Mn |
| Mar 31, 2026 | 2.79 Mn |
| Dec 31, 2025 | 2.48 Mn |
| Sep 30, 2025 | 2.45 Mn |
| Jun 30, 2025 | 2.14 Mn |
| Mar 31, 2025 | 3.74 Mn |
| Dec 31, 2024 | 2.94 Mn |
| Sep 30, 2024 | 2.41 Mn |
| Jun 30, 2024 | 2.03 Mn |
| Mar 31, 2024 | 1.86 Mn |
| Dec 31, 2023 | 1.70 Mn |
| Sep 30, 2023 | 1.60 Mn |
| Jun 30, 2023 | 1.77 Mn |
| Mar 31, 2023 | 3.67 Mn |
| Dec 31, 2022 | 1.38 Mn |
| Sep 30, 2022 | 1.39 Mn |
| Jun 30, 2022 | 1.28 Mn |
| Mar 31, 2022 | 1.38 Mn |
| Dec 31, 2021 | 2.01 Mn |
| Sep 30, 2021 | 1.68 Mn |